mechlorethamine has been researched along with vorinostat in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bradley, B; Parker, SR | 1 |
| Duvic, M | 1 |
3 review(s) available for mechlorethamine and vorinostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment of cutaneous T-cell lymphoma/mycosis fungoides.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antineoplastic Agents; Bexarotene; Biopsy; Cost of Illness; Diphtheria Toxin; Foundations; Humans; Hydroxamic Acids; Interferons; Interleukin-2; Mechlorethamine; Mycosis Fungoides; Neoplasm Staging; Photopheresis; Phototherapy; Physical Examination; Radiotherapy; Recombinant Fusion Proteins; Retinoids; Self-Help Groups; Skin Care; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat | 2006 |
Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diphtheria Toxin; Dose-Response Relationship, Drug; Humans; Hydroxamic Acids; Immunologic Factors; Interferon-alpha; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Purine Nucleosides; Pyrimidinones; Radiotherapy, Adjuvant; Recombinant Fusion Proteins; Retinoids; Sezary Syndrome; Skin Neoplasms; Vorinostat | 2007 |